Navigation Links
Gen-Probe to Webcast Three Upcoming Investor Presentations
Date:2/24/2011

SAN DIEGO, Feb. 24, 2011 /PRNewswire/ -- Gen-Probe Incorporated (Nasdaq: GPRO) announced today that the Company will present at three upcoming investor conferences:

  • RBC Capital Markets' Healthcare Conference in New York at 10 a.m. Eastern Time (ET) on March 2.  The Company also will participate in a panel discussion entitled The Future of Molecular Testing at 3:35 p.m. ET the same day.
  • Cowen and Company's 31st Annual Healthcare Conference in Boston at 10:15 a.m. ET on March 9.
  • Barclays Capital's 2011 Global Healthcare Conference in Miami at 3:15 p.m. ET on March 16.

  • The presentations and the panel discussion will be webcast live and may be accessed through a link on the investors section of Gen-Probe's website at www.gen-probe.com.  The webcasts will be available for 30 days following the events.

    About Gen-ProbeGen-Probe is a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective molecular diagnostic products and services that are used primarily to diagnose human diseases, screen donated human blood, and ensure transplant compatibility.  Gen-Probe has approximately 28 years of expertise in nucleic acid testing (NAT), and received the 2004 National Medal of Technology, America's highest honor for technological innovation, for developing NAT assays for blood screening.  Gen-Probe is headquartered in San Diego and employs approximately 1,400 people. For more information, go to www.gen-probe.com.

    Caution Regarding Forward-Looking StatementsAny statements in this press release about our expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements.  Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual results to differ materially from those expressed or implied.  For information about risks and uncertainties we face and a discussion of our financial statements and footnotes, see documents we have filed with the SEC, including our most recent Form 10-K, and all subsequent periodic filings.  We assume no obligation and expressly disclaim any duty to update any forward-looking statement to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.Contact:Paula IzidoroInvestor Relations858-410-8904
    '/>"/>

    SOURCE Gen-Probe Incorporated
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Gen-Probe Announces Webcast of Third Quarter 2007 Earnings Conference Call
    2. Gen-Probe Submits U.S. Regulatory Application for Additional Approval of PROCLEIX(R) ULTRIO(R) Blood Screening Assay
    3. Gen-Probe Begins U.S. Clinical Study of Molecular Test for Human Papillomavirus, Which Causes Cervical Cancer
    4. Gen-Probe and DiagnoCure Amend Collaboration Agreement Surrounding PCA3-Based Prostate Cancer Tests
    5. Gen-Probe Begins U.S. Clinical Study of PROGENSA(R) PCA3 Assay, New Molecular Test to Help Assess Prostate Cancer Risk
    6. Gen-Probe to Webcast Two Upcoming Investor Presentations
    7. Neogen Acquires Gen-Probes BioKits Food Safety Business
    8. Patrick J. Sullivan Elected to Gen-Probe Board of Directors
    9. Gen-Probe Files US Regulatory Application for Molecular Test to Detect Common Sexually Transmitted Disease Trichomonas Vaginalis
    10. Gen-Probe Announces Webcast of Third Quarter 2010 Earnings Conference Call
    11. Gen-Probe to Webcast Two Upcoming Investor Presentations
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/10/2016)... A Worldwide Clinical Trials expert will ... Victoria Park Plaza in London , 24-25 ... and future advances for late phase research on Wednesday, 24 ... , associate director of project management at Worldwide, will focus ... regulations and standards in late phase research. ...
    (Date:2/10/2016)... Feb. 10, 2016  LexisNexis® Risk Solutions, a ... announced the launch of LexisNexis Provider Performance ... helps improve and optimize the quality and efficiency ... using severity-adjusted scores. By measuring provider performance through ... to deliver better outcomes, improve the patient experience ...
    (Date:2/10/2016)... Feb. 10, 2016 Mast Therapeutics, Inc. ... clinical-stage therapies for sickle cell disease and heart failure, ... of 29,090,910 units at a price to the public ... share of the Company,s common stock and one warrant ... at an exercise price of $0.42 per share. The ...
    Breaking Medicine Technology:
    (Date:2/11/2016)... Viejo, CA (PRWEB) , ... February 11, 2016 , ... ... Pro X users with customizable backdrops in the Christmas edition of the ProDrop ... of the year. Captivate audiences and invoke the spirit of Christmas using ProDrop's wintry ...
    (Date:2/11/2016)... CO. (PRWEB) , ... February 11, 2016 , ... ... people have become more actively engaged in health and wellness best practices in ... importance of riding this trend. February is American Heart Month, which acts as ...
    (Date:2/10/2016)... ... February 10, 2016 , ... The 9th annual meeting ... Congress (WMIC), will be held in New York City, NY on September 7 ... The congress will highlight and emphasize how imaging reveals a greater understanding of ...
    (Date:2/10/2016)... ... February 10, 2016 , ... ... expand dental health services to the developmentally disabled in the Coachella Valley. , ... to a new facility at 71-949 Highway 111, Suite 100-B, in Rancho Mirage, ...
    (Date:2/10/2016)... ... February 10, 2016 , ... Compliancy Group ... associations of medical professionals throughout the country. The Guard was specifically designed to ... and procedures, employee training, regulatory updates, and compliance coaching. , In addition to ...
    Breaking Medicine News(10 mins):